AltMachine shares a report from Phys.Org: Chinese scientists recently reported a de novo route for artificial starch synthesis from carbon dioxide (CO2) for the first time. Relevant results were published in Science on Sept. 24. The new route makes it possible to produce starch, a major component of grains, by industrial manufacturing instead of traditional agricultural planting and opens up a new technical route for synthesizing complex molecules from CO2. The artificial route can produce starch from CO2 with an efficiency 8.5-fold higher than starch biosynthesis in maize, suggesting a big step towards going beyond nature. It provides a new scientific basis for creating biological systems with unprecedented functions. "If the overall cost of the process can be reduced to a level economically comparable with agricultural planting in the future, it is expected to save more than 90% of cultivated land and freshwater resources," said MA Yanhe, corresponding author of the study. In addition, it would also help to avoid the negative environmental impact of using pesticides and fertilizers, improve human food security, facilitate a carbon-neutral bioeconomy, and eventually promote the formation of a sustainable bio-based society.

"A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing," reports Fierce Biotech: We don't like to throw the word "cure" around here. But Excision BioTherapeutics thinks the therapy could replace standard-of-care retroviral therapy, which keeps HIV from replicating but does not remove it from the body. That means patients stay on the treatment, which can cause serious side effects and affect quality of life. Now with the start of human testing, the real path to see if this new and lauded tech can accomplish this really begins.

HIV integrates its genetic material into the genome of a host cell, meaning available therapies just can't remove it. A team of scientists at Temple University and the University of Nebraska Medical Center managed to remove the virus completely from mice during preclinical testing using a combination of CRISPR and antiretroviral therapy. They also found no adverse events that could be linked to the therapy in the study, published back in 2019... EBT-101 has since been tested in nonhuman primates, which showed it reached every tissue in the body where HIV reservoirs reside.

Excision licensed the therapy from the universities with a goal of moving it into clinical trials. Now, the FDA is on board. The biotech plans to initiate a phase 1/2 clinical trial later this year, according to the statement.

The technology used by Excision was licensed from the lab of famed CRISPR pioneer Jennifer Doudna. The company is also working on similar treatments for other viruses, including herpes and hepatitis B.

A crop of companies want to make sperm-freezing a routine procedure for young men, as employers start to offer it as a benefit. From a report: For decades, the conversation about waning fertility has been focused largely on women. Think of Marisa Tomei stomping on the floorboards of a front porch to emulate her biological clock ticking in "My Cousin Vinny." More employers cover the cost of cryogenic egg freezing as a workplace benefit. Recently, a small group of biotech startups have hatched, dedicated to what they say is an underserved market: male fertility. Armed with recent scientific research suggesting that the quality of sperm is declining in the West, the companies are trying to make sperm-freezing a routine procedure for young, healthy men, one covered by health insurance and free of stigma.

"My fundamental belief is that if the product is affordable, this should be a no-brainer for every man," says Khaled Kteily, the 32-year-old founder of Legacy, one of the companies that Mr. Alam used to freeze his sperm. "I believe that in the future," he adds, "this will be something that parents will buy for their kids as a not-so-subtle gift." The push to make a case for its business is starting to catch on. The company recently struck a deal to eventually provide free sperm testing and storage to all active duty service members in the U.S. military, starting with the Navy SEALs, of which there are about 1,200 a year, and expanding next to all special operations forces. The Navy didn't respond to a request for comment. Soldiers regularly experience risky situations and time away from their partners, says Ellen Gustafson, a Navy wife and co-founder of the Military Family Coalition, a nonprofit that advocates for coverage of fertility medicine for members of the armed forces.

What is was like competing with -- and dealing with the wreckage of -- the most infamous startup in the world. From a report: Theranos' collapse was as public as it gets for a Silicon Valley unicorn, beginning in 2015 with a widely read series of articles by former Wall Street Journal reporter John Carreyrou, who revealed that Theranos' technology was far less effective than advertised. The debacle went on to inspire the bestselling book Bad Blood by Carreyrou, an HBO documentary, and a forthcoming Hulu series starring Amanda Seyfried. This week, Holmes' highly anticipated trial begins in earnest. Jurors were sworn in last Thursday, and opening statements will begin on Wednesday. Prosecutors have charged Holmes with multiple counts of fraud and conspiracy related to the ascent and operations of Theranos, though she maintains her innocence. Once famous for a supposedly innovative approach to blood testing, now infamous for allegedly faking it, the names Theranos and Elizabeth Holmes aren't fading away anytime soon.

All of this has had a ripple effect for other companies that, like Theranos, were trying to make blood drawing and diagnostics easier for consumers. I spoke to five such companies recently about how they have dealt with unwelcome comparisons to Theranos, which has bedeviled the sector ever since Carreyrou's first piece on the subject. One company I reached out to expressed that it was hesitant to even appear in an article about Theranos. Even before Theranos imploded, its outsize presence was felt by other companies in the blood testing industry, for better and worse. "In the beginning, when Theranos was on its up slope, people were asking how we were ever going to compete with a company like Theranos when they've raised a billion dollars," said Daniel Levner, co-founder of Sight Diagnostics, a biotech company that sells a device that can conduct a blood count analysis from a finger prick.

Yet when Carreyrou's pieces began appearing in the Journal, comparisons to Theranos became a curse for its peers. "In pretty much every conversation we had for a year, Theranos would come up," said John Lewis, founder and CEO of Nanostics, a biotech company that sells a device that can use a very small amount of blood to diagnose and predict diseases. "Most people recognized that Theranos was mostly just bad founders, but it certainly was on everybody's mind." Lewis recounts that his company, which had only existed for a year and a half at the time, was in a pitch competition right as the Theranos scandal was coming to light. The very first question they got at the event was how the Nanostics product compared to Theranos'. From there, Nanostics took pains to distinguish itself from Theranos, down to the smallest details. For instance, the company in its promotional materials tried to stay away from Theranos' famous selling point of diagnosing diseases from a single drop of blood. "Our initial plan was to go out saying that we can detect disease signatures with a single drop of blood, but that was literally just when Theranos was going down for stating that they could do that when they couldn't," Lewis recalled. "So in our texts we said, 'two drops of blood.'"

A prenatal test taken by millions of pregnant women globally was developed by Chinese gene company BGI Group in collaboration with the Chinese military and is being used by the firm to collect genetic data, a Reuters review of publicly available documents found. From the report: The report is the first to reveal that the company collaborated with the People's Liberation Army (PLA) to develop and improve the test, taken in early pregnancy, as well as the scope of BGI's storage and analysis of the data. The United States sees BGI's efforts to collect and analyze human gene data as a national security threat. China's biggest genomics firm, BGI began marketing the test abroad in 2013. Branded NIFTY, it is among the world's top selling non-invasive prenatal tests (NIPT). These screen a sample of blood from a pregnant woman to detect abnormalities such as Down's syndrome in a developing fetus. So far more than 8 million women globally have taken BGI's prenatal tests, BGI has said. NIFTY is sold in at least 52 countries, including Britain, Europe, Canada, Australia, Thailand and India, but not the United States.

BGI uses leftover blood samples sent to its laboratory in Hong Kong and genetic data from the tests for population research, the company confirmed to Reuters. Reuters found the genetic data of over 500 women who took the test, including women in Europe and Asia, is also stored in the government-funded China National GeneBank in Shenzhen, which BGI runs. Reuters found no evidence BGI violated privacy agreements or regulations; the company said it obtains signed consent and destroys overseas samples and data after five years. "At no stage throughout the testing or research process does BGI have access to any identifiable personal data," the company said. However, the test's privacy policy says data collected can be shared when it is "directly relevant to national security or national defense security" in China. BGI said it "has never been asked to provide -- nor provided -- data from its NIFTY tests to Chinese authorities for national security or national defense purposes." "Non-invasive prenatal testing kits marketed by Chinese biotech firms serve an important medical function, but they can also provide another mechanism for the People's Republic of China and Chinese biotech companies to collect genetic and genomic data from around the globe," the U.S. National Counterintelligence and Security Center said.

China's foreign ministry said Reuters' findings reflected "groundless accusations and smears" of U.S. agencies.

USA Today reports: Companies like Moderna and Pfizer's partner BioNTech, whose names are familiar from COVID-19 vaccines, are using mRNA to spur cancer patients' bodies to make vaccines that will — hopefully — prevent recurrences and treatments designed to fight off advanced tumors. If they prove effective, which won't be known for at least another year or two, they could be added to the arsenal of immune therapies designed to get the body to fight off its own tumors...

Over the last decade, pharmaceutical companies around the world have been developing new ways to train the body's immune system to fight off tumors, particularly melanoma. They had learned how to remove a brake installed by tumors, unleashing the warriors of the immune system. Ten years ago, only about 5% of people with advanced melanoma survived for five years. Now, nearly half make it that long. Trials of mRNA cancer vaccines aim to boost that number even higher by adding soldiers to the fight... Once a tumor has been largely removed through surgery, a vaccine can help generate new immune soldiers known as T cells... A computer algorithm analyzes the mutations distinct to the cancer cells, looking for ones that trigger the production of T cells, said Melissa J. Moore, Moderna's chief scientific officer, of platform research. So far, she said, Moderna, working with partner Merck, has tested these personalized vaccines in about 100 patients. They aim eventually to make a personalized mRNA vaccine within about 45 days after the patient's cancer surgery, during their recovery...

Mutated cancer cells have proteins on their surface that can be targeted by an mRNA vaccine. For a tumor that has, say, five common mutations, a patient could get a combination of five of these vaccines. On Friday, BioNTech announced it was launching a new trial for this approach, testing it in 120 melanoma patients Europe, the United Kingdom, Australia and the U.S. The new treatment, given in connection with an antibody from Regeneron, is aimed at four tumor-associated antigens. More than 90% of melanoma tumors contain at least one of the four.
The U.S. federal government now lists 29 studies underway or that will be soon investigating mRNA cancer vaccines, according to the article.

And Dr. Stephen Hahn, who had a career as an oncologist before running the Food and Drug Administration from 2019 until early this year, "said he's more optimistic this time because of how much researchers have learned about the role the immune system plays in cancer. 'That gives us an edge to maybe finally get to the place where we need to be.'"

Slashdot reader AmiMoJo shares a report from Reuters: Scientific advances from deep brain stimulation to wearable scanners are making manipulation of the human mind increasingly possible, creating a need for laws and protections to regulate use of the new tools, top neurologists said on Thursday.

A set of "neuro-rights" should be added to the Universal Declaration of Human Rights adopted by the United Nations, said Rafael Yuste, a neuroscience professor at New York's Columbia University and organizer of the Morningside Group of scientists and ethicists proposing such standards. Five rights would guard the brain against abuse from new technologies — rights to identity, free will and mental privacy along with the right of equal access to brain augmentation advances and protection from algorithmic bias, the group says.

"If you can record and change neurons, you can in principle read and write the minds of people," Yuste said during an online panel at the Web Summit, a global tech conference.

"This is not science fiction. We are doing this in lab animals successfully."

"A new kind of COVID-19 vaccine could be available as soon as this summer," reports NPR: It's what's known as a protein subunit vaccine. It works somewhat differently from the current crop of vaccines authorized for use in the U.S. but is based on a well-understood technology and doesn't require special refrigeration.

In general, vaccines work by showing people's immune systems something that looks like the virus but really isn't. Consider it an advance warning; if the real virus ever turns up, the immune system is ready to try to squelch it. In the case of the coronavirus, that "something" is one of the proteins in the virus — the spike protein. The vaccines made by Johnson & Johnson, Moderna and Pfizer contain genetic instructions for the spike protein, and it's up to the cells in our bodies to make the protein itself.

The first protein subunit COVID-19 vaccine to become available will likely come from the biotech company, Novavax. In contrast to the three vaccines already authorized in the U.S., it contains the spike protein itself — no need to make it, it's already made — along with an adjuvant that enhances the immune system's response, to make the vaccine even more protective.

Protein subunit vaccines made this way have been around for a while. There are vaccines on the market for hepatitis B and pertussis based on this technology.
And meanwhile, the article points out, there's also another company — the pharmaceutical giant Sanofi — that's also working on its own protein subunit vaccine against the coronavirus.

Science is once again casting doubt on the notion that we could live to be nearly as old as the biblical Methuselah or Mel Brooks' 2,000-year-old man. From a report: New research research [PDF] from Singapore-base biotech company Gero looks at how well the human body bounces back from disease, accidents or just about anything else that puts stress on its systems. This basic resilience declines as people age, with an 80-year-old requiring three times as long to recover from stresses as a 40-year-old on average. This should make sense if you've ever known an elderly person who has taken a nasty fall. Recovery from such a spill can be lif- threatening for a particularly frail person, whereas a similar fall might put a person half as old out of commission for just a short time and teenagers might simply dust themselves off and keep going.

Extrapolate this decline further, and human body resilience is completely gone at some age between 120 and 150, according to new analysis performed by the researchers. In other words, at some point your body loses all ability to recover from pretty much any potential stressor. The researchers arrived at this conclusion by looking at health data for large groups from the US, the UK and Russia. They looked at blood cell counts as well as step counts recorded by wearables. As people experienced different stressors, fluctuations in blood cell and step counts showed that recovery time grew longer as individuals grew older. "Aging in humans exhibits universal features common to complex systems operating on the brink of disintegration," Peter Fedichev, co-founder and CEO of Gero, said in a statement.

Implantable miniaturized medical devices that wirelessly transmit data "are transforming healthcare and improving the quality of life for millions of people," writes Columbia University, noting the devices are "widely used to monitor and map biological signals, to support and enhance physiological functions, and to treat diseases."

Long-time Slashdot reader sandbagger shares the university's newest announcement: These devices could be used to monitor physiological conditions, such as temperature, blood pressure, glucose, and respiration for both diagnostic and therapeutic procedures. To date, conventional implanted electronics have been highly volume-inefficient — they generally require multiple chips, packaging, wires, and external transducers, and batteries are often needed for energy storage... Researchers at Columbia Engineering report that they have built what they say is the world's smallest single-chip system, consuming a total volume of less than 0.1 mm cubed. The system is as small as a dust mite and visible only under a microscope...

"We wanted to see how far we could push the limits on how small a functioning chip we could make," said the study's leader Ken Shepard, Lau Family professor of electrical engineering and professor of biomedical engineering. "This is a new idea of 'chip as system' — this is a chip that alone, with nothing else, is a complete functioning electronic system. This should be revolutionary for developing wireless, miniaturized implantable medical devices that can sense different things, be used in clinical applications, and eventually approved for human use...."

The chip, which is the entire implantable/injectable mote with no additional packaging, was fabricated at the Taiwan Semiconductor Manufacturing Company with additional process modifications performed in the Columbia Nano Initiative cleanroom and the City University of New York Advanced Science Research Center (ASRC) Nanofabrication Facility. Shepard commented, "This is a nice example of 'more than Moore' technology—we introduced new materials onto standard complementary metal-oxide-semiconductor to provide new function. In this case, we added piezoelectric materials directly onto the integrated circuit to transducer acoustic energy to electrical energy...." The team's goal is to develop chips that can be injected into the body with a hypodermic needle and then communicate back out of the body using ultrasound, providing information about something they measure locally.

The current devices measure body temperature, but there are many more possibilities the team is working on.

CNN recently reported on "a batch" of new studies published Wednesday — with one quantifying how much immunity improves after the second dose, and others showing how well coronavirus vaccines work against new variants of the virus: The first nationwide study of coronavirus vaccination, done in Israel, showed Pfizer/BioNtech's vaccine works far better after two doses. Two shots of the vaccine provided greater than 95% protection from infection, severe illness and death, Dr. Eric Haas of the Israel Ministry of Health and colleagues reported in the Lancet medical journal. "Two doses of BNT162b2 are highly effective across all age groups in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalizations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant," they wrote. The B.1.1.7 variant, first seen in Britain, has spread widely and is now the most common new variant seen in the US. It was also common in Israel when the study was done...

"By 14 days after vaccination, protections conferred by a second dose [of the Pfizer vaccine] increased to 96.5% protection against infection, 98% against hospitalization, and 98.1% against death," the team wrote. But people who got only one dose of the vaccine were far less protected. One dose alone gave just 57.7% protection against infection, 75.7% against hospitalization, and 77% against death....

Separately, a team in the Gulf state of Qatar looked at the efficacy of Pfizer's vaccine in the population there when B.1.351 and B.1.1.7 were both circulating. They found reassuring results. "The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% at 14 or more days after the second dose. The effectiveness against any documented infection with the B.1.351 variant was 75%," the researchers wrote in a letter to the New England Journal of Medicine...

Vaccine maker Moderna reported Wednesday that a booster shot delivering a half-dose of its current vaccine revs up the immune response against both B.1.351 and P.1. And a booster dose formulated specifically to match B.1.351 was even more effective, Moderna said in a statement...

In another study, vaccine maker Novavax confirmed earlier findings that showed its vaccine protects against B.1.351.

An anonymous reader quotes a report from the BBC: The world's biggest jeweller, Pandora, says it will no longer sell mined diamonds and will switch to exclusively laboratory-made diamonds. Concerns about the environment and working practices in the mining industry have led to growing demand for alternatives to mined diamonds. Pandora's chief executive, Alexander Lacik, told the BBC the change was part of a broader sustainability drive. He said the firm was pursuing it because "it's the right thing to do." They are also cheaper: "We can essentially create the same outcome as nature has created, but at a very, very different price." Mr Lacik explains they can be made for as little as "a third of what it is for something that we've dug up from the ground."

Pandora's lab-made diamonds are being made in Britain, and the UK is the first country where they will be sold. The new diamond jewelry will start at $350. [...] One problem with lab-made diamonds, though, is that they can take a lot of energy to produce. Between 50% and 60% of them come from China, where they are made in a process known as "high-pressure, high-temperature technology." The use of coal powered electricity is widespread. However in the United States, the biggest retail market for lab-grown diamonds, there is a greater focus on using renewable energy. The largest US producer, Diamond Foundry, says its process is "100% hydro-powered, meaning zero emissions." Both types are chemically and physically identical to mined diamonds.

According to The Byte, the co-founder of brain implant startup Neuralink, Max Hodak, announced he's leaving the company. From the report: Hodak, who started the ultra-ambitious venture with Elon Musk and had until recently served as its president, didn't say why he was leaving the company or on what terms. In other words, it's not currently clear whether he left voluntary or was fired. "I am no longer at Neuralink (as of a few weeks ago)," he wrote in a tweet. "I learned a ton there and remain a huge cheerleader for the company! Onward to new things." Last month, Hodak made headlines when he tweeted that the startup has the technological advances and savvy to create its own "Jurassic Park."

Scientific American has published an opinion piece by the principle investigator for a project called SPARK, launched five years ago "to harness the power of big data by engaging hundreds of thousands of individuals with autism and their family members to participate in research."

The article calls autism "a remarkably heterogeneous disorder that affects more than five million Americans and has no FDA-approved treatments," arguing that the more people who participate in their research, "the deeper and richer these data sets become, catalyzing research that is expanding our knowledge of both biology and behavior to develop more precise approaches to medical and behavioral issues." SPARK is the world's largest autism research study to date with over 250,000 participants, more than 100,000 of whom have provided DNA samples through the simple act of spitting in a tube. We have generated genomic data that have been de-identified and made available to qualified researchers. SPARK has itself been able to analyze 19,000 genes to find possible connections to autism; worked with 31 of the nation's leading medical schools and autism research centers; and helped thousands of participating families enroll in nearly 100 additional autism research studies.

Genetic research has taught us that what we commonly call autism is actually a spectrum of hundreds of conditions that vary widely among adults and children. Across this spectrum, individuals share core symptoms and challenges with social interaction, restricted interests and/or repetitive behaviors. We now know that genes play a central role in the causes of these "autisms," which are the result of genetic changes in combination with other causes including prenatal factors. To date, research employing data science and machine learning has identified approximately 150 genes related to autism, but suggests there may be as many as 500 or more...

But in order to get answers faster and be certain of these results, SPARK and our research partners need a huge sample size: "bigger data." To ensure an accurate inventory of all the major genetic contributors, and learn if and how different genetic variants contribute to autistic behaviors, we need not only the largest but also the most diverse group of participants. The genetic, medical and behavioral data SPARK collects from people with autism and their families is rich in detail and can be leveraged by many different investigators. Access to rich data sets draws talented scientists to the field of autism science to develop new methods of finding patterns in the data, better predicting associated behavioral and medical issues, and, perhaps, identifying more effective supports and treatments...

We know that big data, with each person representing their unique profile of someone impacted by autism, will lead to many of the answers we seek.

Long-time Slashdot reader destinyland writes: The New York Times tells the story of Hungarian-born Dr. Kariko, whose father was a butcher and who growing up had never met a scientist — but knew they wanted to be one. Despite earning a Ph.D. at Hungary's University of Szeged and working as a postdoctoral fellow at its Biological Research Center, Kariko never found a permanent position after moving to the U.S., "instead clinging to the fringes of academia."

Now 66 years old, Dr. Kariko is suddenly being hailed as "one of the heroes of Covid-19 vaccine development," after spending an entire career focused on mRNA, "convinced mRNA could be used to instruct cells to make their own medicines, including vaccines."
From the article: For many years her career at the University of Pennsylvania was fragile. She migrated from lab to lab, relying on one senior scientist after another to take her in. She never made more than $60,000 a year... She needed grants to pursue ideas that seemed wild and fanciful. She did not get them, even as more mundane research was rewarded. "When your idea is against the conventional wisdom that makes sense to the star chamber, it is very hard to break out," said Dr. David Langer, a neurosurgeon who has worked with Dr. Kariko... Kariko's husband, Bela Francia, manager of an apartment complex, once calculated that her endless workdays meant she was earning about a dollar an hour.
The Times also describes a formative experience in 1989 with cardiologist Elliot Barnathan: One fateful day, the two scientists hovered over a dot-matrix printer in a narrow room at the end of a long hall. A gamma counter, needed to track the radioactive molecule, was attached to a printer. It began to spew data.

Their detector had found new proteins produced by cells that were never supposed to make them — suggesting that mRNA could be used to direct any cell to make any protein, at will.

"I felt like a god," Dr. Kariko recalled.
Yet Kariko was eventually left without a lab or funds for research, until a chance meeting at a photocopying machine led to a partnership with Dr. Drew Weissman of the University of Pennsylvania: "We both started writing grants," Dr. Weissman said. "We didn't get most of them. People were not interested in mRNA. The people who reviewed the grants said mRNA will not be a good therapeutic, so don't bother.'" Leading scientific journals rejected their work. When the research finally was published, in Immunity, it got little attention... "We talked to pharmaceutical companies and venture capitalists. No one cared," Dr. Weissman said. "We were screaming a lot, but no one would listen."

Eventually, though, two biotech companies took notice of the work: Moderna, in the United States, and BioNTech, in Germany. Pfizer partnered with BioNTech, and the two now help fund Dr. Weissman's lab.

"Scientists have demonstrated the first human use of a wireless brain-computer interface, a potential breakthrough for people with paralysis," reports The Next Web (in a story shared by Slashdot reader Hmmmmmm): While traditional BCIs are tethered to users via cables, the new system — called BrainGate — replaces the cords with a small transmitter affixed atop a users' head. The unit then connects to an electrode array implanted in the brain's motor cortex. In a clinical trial, two participants with paralysis used the system to point, click, and type on a standard tablet computer. They both achieved similar typing speeds and point-and-click accuracy as those attained with wired systems.

The researchers say it's the first time a device has transmitted the full spectrum of signals recorded by a sensor in the brain's motor cortex.

"New vaccine trials hold great promise in the management of an East African strain of African swine fever, one of the most devastating diseases to afflict pigs," writes Cornell's Alliance for Science (a group who gives its mission as correcting misinformation and countering conspiracy theories slowing progress on issues including synthetic biology and agricultural innovations).

Slashdot reader wooloohoo shares their report: Scientists at the International Livestock Research Institute (ILRI) are employing CRISPR Cas9 editing and synthetic biology to modify the ASFV genome in order to attenuate the virus for a live vaccine to help reduce deaths from African swine fever. Up to 10 vaccine candidates have been lined up for tests, in a project that commenced in 2016...

African swine fever is present in 26 African countries, Steinaa observed, as well as in parts of Asia and Europe. An effective vaccine could be a breakthrough for pig farmers across the globe... With a 100 percent fatality rate and a highly contagious nature, African swine fever poses a potent threat to the global pig farming industry. The rapid spread of the disease portends social and economic disruptions wherever it strikes.

Slashdot reader wooloohoo shares a new article from Cornell's Alliance for Science, a group who gives its mission as correcting misinformation and countering conspiracy theories slowing progress on issues including synthetic biology and agricultural innovations: There are two types of chickens: the broilers that we eat and the layers that produce the eggs. The layers don't have enough meat to make them useful for human consumption and since only hens can lay eggs, that leaves the male layers useless. As a result, billions of newly hatched male layer chicks are killed each year.

Now the Israeli ag-tech startup eggXYt has found a way to humanely address this dilemma through the use of CRISPR — the gene editing technique that allows scientists to make targeted, specific genetic tweaks...

By using CRISPR, eggXYt's scientists can edit the genes of chickens to make them lay sex-detectable eggs... The global egg industry saves the costs and the ethical conundrum of killing half of its product and billions of additional eggs are added to the global market to help meet growing demand.

U.S. plant-based protein company Beyond Meat has signed global supply deals with fast food firms McDonald's and Yum! Brands, which includes KFC, Pizza Hut, Taco Bell and others. AgFunderNews reports: The three-year strategic agreement with McDonald's will see Beyond Meat become the 'preferred supplier' of patties for the fast food chain's new McPlant plant-based burger. Under their separate strategic partnership, Beyond Meat and Yum! Brands will co-develop a range of exclusive plant-based protein menu items for the latter's KFC, Pizza Hut, and Taco Bell chains.

Bruce Friedrich, executive director of the Good Food Institute, said in comments sent to AFN that the two deals represent "the clearest sign yet that the future of meat will be plant-based." "The world's largest restaurant chains are placing plant-based meat directly on the plates of millions of customers around the world," he said. "With more restaurants and revenue than any other food chains on the planet, McDonald's and Yum! Brands will bring plant-based meat onto the mainstream menus of millions of people. When these restaurant chains move, the entire food industry takes notice."

A new research study at the University of Missouri is using CRISPR gene-editing technology to produce mosquitoes that are unable to replicate Zika virus and therefore cannot infect a human through biting. Slashdot reader wooloohoo shared an announcement from Cornell's Alliance for Science: Alexander Franz, an associate professor in the MU College of Veterinary Medicine, collaborated with researchers at Colorado State University... Their work was recently published in the journal Viruses. Franz added that the genetic modification is inheritable, so future generations of the altered mosquitoes would be resistant to Zika virus as well... "[W]e are simply trying to expand the toolbox and provide a solution by genetically modifying the mosquitoes to become Zika-resistant while keeping them alive at the same time."

Franz' research is designed to help prevent another outbreak of Zika virus disease from occurring while also addressing concerns that have some have raised about reducing populations of mosquitoes, which are a food source for some animals...

The study was funded by the National Institutes of Health.